Margetuximab Access Program for Patients with HER2+ Breast Cancer
Sponsor: TerSera Therapeutics LLC
ClinicalTrials ID:NCT03133988
This program allows patients with HER2+ breast cancer, who have already received treatment, to access the drug margetuximab if it is believed to offer more benefits than risks.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The Expanded Access program is designed to provide the drug margetuximab to patients with HER2+ breast cancer who have already undergone treatment. This is for cases where the potential benefits of using margetuximab outweigh the possible risks involved.
Description
TerSera Therapeutics LLC is offering a program where doctors can request access to margetuximab for individual patients with HER2+ breast cancer. This is considered on a case-by-case basis, meaning each request is evaluated individually. The program is intended for patients who may not qualify for existing clinical trials of margetuximab but could potentially benefit from the drug. Doctors are encouraged to explore all approved treatments and ongoing clinical trials for the patient's condition before applying for this program.
Eligibility Criteria
Inclusion Criteria
- Doctors can request access to margetuximab for patients who are not eligible for current clinical trials of the drug.
- Before applying for this program, doctors should consider all approved treatments and ongoing clinical trials for the patient's condition.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.